Anticancer Drugs
The past decades have seen major developments in the understanding of the cellular and molecular biology of cancer. Significant progress has been achieved regarding long-term survival for the patients of many cancers with the use of tamoxifen for treatment of breast cancer, treatment of chronic myel...
Saved in:
: | |
---|---|
Year of Publication: | 2019 |
Language: | English |
Physical Description: | 1 electronic resource (214 p.) |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
993548401904498 |
---|---|
ctrlnum |
(CKB)4100000010106178 (oapen)https://directory.doabooks.org/handle/20.500.12854/40955 (EXLCZ)994100000010106178 |
collection |
bib_alma |
record_format |
marc |
spelling |
O’Boyle, Niamh M auth Anticancer Drugs MDPI - Multidisciplinary Digital Publishing Institute 2019 1 electronic resource (214 p.) text txt rdacontent computer c rdamedia online resource cr rdacarrier The past decades have seen major developments in the understanding of the cellular and molecular biology of cancer. Significant progress has been achieved regarding long-term survival for the patients of many cancers with the use of tamoxifen for treatment of breast cancer, treatment of chronic myeloid leukaemia with imatinib, and the success of biological drugs. The transition from cytotoxic chemotherapy to targeted cancer drug discovery and development has resulted in an increasing selection of tools available to oncologists. In this Special Issue of Pharmaceuticals, we highlight the opportunities and challenges in the discovery and design of innovative cancer therapies, novel small-molecule cancer drugs and antibody–drug conjugates, with articles covering a variety of anticancer therapies and potential relevant disease states and applications. Significant efforts are being made to develop and improve cancer treatments and to translate basic research findings into clinical use, resulting in improvements in survival rates and quality of life for cancer patients. We demonstrate the possibilities and scope for future research in these areas and also highlight the challenges faced by scientists in the area of anticancer drug development leading to improved targeted treatments and better survival rates for cancer patients. English graphene oxide indole androgens cyclooxygenase-2 cyclooxygenase-1 heteropolysaccharide drug conjugation drug delivery ellipticine chemical linker oesophageal cancer antiproliferative activity topoisomerase II ?-lactam DSD antibody topoisomerase inhibitors magnetic targeting cisplatin resistance steroidogenesis [18F]FDG PET/CT heterocyclic chemistry dehydroepiandrosterone antimitotic 3-vinylazetidin-2-ones glioblastoma and cancer therapy intestinal mucositis Combretastatin A-4 metabolism anti-cancer drugs maghemite COX-1 inhibitor anticancer CYP17A1 conjugate and hybrid drugs inflammation snticancer drugs P450c17 tumorigenesis cisplatin biomarker profiling cancer drug design tubulin cytochrome P450 5-fluorouracil prostate cancer abiraterone NCI screen radiation cancer immunotherapy microtubule targeted drugs cancer treatment resistance 3-03921-586-8 Meegan, Mary J auth |
language |
English |
format |
eBook |
author |
O’Boyle, Niamh M |
spellingShingle |
O’Boyle, Niamh M Anticancer Drugs |
author_facet |
O’Boyle, Niamh M Meegan, Mary J |
author_variant |
n m o nm nmo |
author2 |
Meegan, Mary J |
author2_variant |
m j m mj mjm |
author_sort |
O’Boyle, Niamh M |
title |
Anticancer Drugs |
title_full |
Anticancer Drugs |
title_fullStr |
Anticancer Drugs |
title_full_unstemmed |
Anticancer Drugs |
title_auth |
Anticancer Drugs |
title_new |
Anticancer Drugs |
title_sort |
anticancer drugs |
publisher |
MDPI - Multidisciplinary Digital Publishing Institute |
publishDate |
2019 |
physical |
1 electronic resource (214 p.) |
isbn |
3-03921-587-6 3-03921-586-8 |
illustrated |
Not Illustrated |
work_keys_str_mv |
AT oboyleniamhm anticancerdrugs AT meeganmaryj anticancerdrugs |
status_str |
n |
ids_txt_mv |
(CKB)4100000010106178 (oapen)https://directory.doabooks.org/handle/20.500.12854/40955 (EXLCZ)994100000010106178 |
carrierType_str_mv |
cr |
is_hierarchy_title |
Anticancer Drugs |
author2_original_writing_str_mv |
noLinkedField |
_version_ |
1787551667441369091 |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>03879nam-a2200925z--4500</leader><controlfield tag="001">993548401904498</controlfield><controlfield tag="005">20231214133528.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr|mn|---annan</controlfield><controlfield tag="008">202102s2019 xx |||||o ||| 0|eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">3-03921-587-6</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(CKB)4100000010106178</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(oapen)https://directory.doabooks.org/handle/20.500.12854/40955</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(EXLCZ)994100000010106178</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">O’Boyle, Niamh M</subfield><subfield code="4">auth</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Anticancer Drugs</subfield></datafield><datafield tag="260" ind1=" " ind2=" "><subfield code="b">MDPI - Multidisciplinary Digital Publishing Institute</subfield><subfield code="c">2019</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 electronic resource (214 p.)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The past decades have seen major developments in the understanding of the cellular and molecular biology of cancer. Significant progress has been achieved regarding long-term survival for the patients of many cancers with the use of tamoxifen for treatment of breast cancer, treatment of chronic myeloid leukaemia with imatinib, and the success of biological drugs. The transition from cytotoxic chemotherapy to targeted cancer drug discovery and development has resulted in an increasing selection of tools available to oncologists. In this Special Issue of Pharmaceuticals, we highlight the opportunities and challenges in the discovery and design of innovative cancer therapies, novel small-molecule cancer drugs and antibody–drug conjugates, with articles covering a variety of anticancer therapies and potential relevant disease states and applications. Significant efforts are being made to develop and improve cancer treatments and to translate basic research findings into clinical use, resulting in improvements in survival rates and quality of life for cancer patients. We demonstrate the possibilities and scope for future research in these areas and also highlight the challenges faced by scientists in the area of anticancer drug development leading to improved targeted treatments and better survival rates for cancer patients.</subfield></datafield><datafield tag="546" ind1=" " ind2=" "><subfield code="a">English</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">graphene oxide</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">indole</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">androgens</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cyclooxygenase-2</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cyclooxygenase-1</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">heteropolysaccharide</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">drug conjugation</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">drug delivery</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">ellipticine</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">chemical linker</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">oesophageal cancer</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">antiproliferative activity</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">topoisomerase II</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">?-lactam</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">DSD</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">antibody</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">topoisomerase inhibitors</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">magnetic targeting</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cisplatin resistance</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">steroidogenesis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">[18F]FDG PET/CT</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">heterocyclic chemistry</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">dehydroepiandrosterone</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">antimitotic</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">3-vinylazetidin-2-ones</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">glioblastoma</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">and cancer therapy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">intestinal mucositis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Combretastatin A-4</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">metabolism</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">anti-cancer drugs</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">maghemite</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">COX-1 inhibitor</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">anticancer</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">CYP17A1</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">conjugate and hybrid drugs</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">inflammation</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">snticancer drugs</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">P450c17</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">tumorigenesis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cisplatin</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">biomarker profiling</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cancer drug design</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">tubulin</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cytochrome P450</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">5-fluorouracil</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">prostate cancer</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">abiraterone</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">NCI screen</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">radiation</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cancer immunotherapy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">microtubule targeted drugs</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cancer</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">treatment resistance</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">3-03921-586-8</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Meegan, Mary J</subfield><subfield code="4">auth</subfield></datafield><datafield tag="906" ind1=" " ind2=" "><subfield code="a">BOOK</subfield></datafield><datafield tag="ADM" ind1=" " ind2=" "><subfield code="b">2023-12-15 05:56:46 Europe/Vienna</subfield><subfield code="f">system</subfield><subfield code="c">marc21</subfield><subfield code="a">2020-02-01 22:26:53 Europe/Vienna</subfield><subfield code="g">false</subfield></datafield><datafield tag="AVE" ind1=" " ind2=" "><subfield code="i">DOAB Directory of Open Access Books</subfield><subfield code="P">DOAB Directory of Open Access Books</subfield><subfield code="x">https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5338783130004498&Force_direct=true</subfield><subfield code="Z">5338783130004498</subfield><subfield code="b">Available</subfield><subfield code="8">5338783130004498</subfield></datafield></record></collection> |